摘要
多药耐药是近年来乳腺癌治疗研究的困扰之一。目前,乳腺癌耐药蛋白(BCRP)、肺耐药蛋白(LRP)和胸苷酸合成酶(TS)在乳腺癌中的研究已成为热点,有望成为一种新的治疗靶点。本文对其基因定位、编码蛋白的结构、分布和生理功能进行了阐述,且概述了目前BCRP、LRP和TS耐药机制、逆转措施以及临床意义的研究进展。
Multidrug resistance（ MDR）is one of curses on the study of breast cancer therapy in recent years. Resistance related proteins, such as breasl cancer resistance protein （BCRP） and lung resistance protein （LRP） anti thymidylate synthase（TS）, have been demonstrated to play an important role in MDR of breast （ranter,anti these proteins might be new therapeutic targets. This paper elaborated their gene location,coding protein,distribution and physiological function,meanwhile summarized the resistance mechanisms of BCRP, LRP anti TS,antl the strategies and importanee for multidrug resistance shift.
出处
《医学综述》
2009年第21期3216-3218,共3页
Medical Recapitulate
关键词
乳腺癌耐药蛋白
肺耐药蛋白
胸苷酸合成酶
多药耐药
Breast cancer resistance protein
Lung resistance protein
Thymidylate synthase
Muhidrug resistance
